Recently published research from Global Markets Direct, "Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 05/15/2014 -- Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014
Global Markets Direct's, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014', provides an overview of the Multiple Myeloma (Kahler's Disease)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects.
View Full Report Details and Table of Contents
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Companies Mentioned in this Report: Johnson & Johnson, F. Hoffmann-La Roche Ltd., Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc, Seattle Genetics, Inc., Biotest AG, Merck & Co., Inc., Gamida Cell Ltd., BioLineRx, Ltd., Amorfix Life Sciences Ltd., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Sigma-Tau S.p.A., Astex Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Santaris Pharma A/S, Celgene Corporation, Onyx Pharmaceuticals, Inc., XTL Biopharmaceuticals Ltd., MannKind Corporation, Merck KGaA, 4SC AG, EntreMed, Inc., Gentium S.p.A., AEterna Zentaris Inc., ImmunoCellular Therapeutics, Ltd., Immunomedics, Inc., Compugen Ltd., Patrys Limited, Curis, Inc., BioInvent International AB, JW Pharmaceutical Corporation, Innate Pharma SA, Transgene Biotek Limited, Cellerant Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Chroma Therapeutics Ltd., CIMAB S.A., Actinium Pharmaceuticals, Inc., Acceleron Pharma, Inc., Priaxon AG, Hutchison MediPharma Limited, Vivolux AB, Altor BioScience Corporation, Coronado Biosciences, Inc., Vaccinex, Inc., CanBas Co., Ltd., Axelar AB, Onconova Therapeutics, Inc., Selexys Pharmaceuticals Corporation, Immune System Therapeutics Ltd., Concert Pharmaceuticals, Inc., Enceladus Pharmaceuticals BV, Immunocore Limited, Tragara Pharmaceuticals, Inc., Pharma Mar, S.A., KaloBios Pharmaceuticals, Inc., AB Science, Anthera Pharmaceuticals, Inc., CureTech Ltd., AVEO Pharmaceuticals, Inc., Janssen Biotech, Inc., Elara Pharmaceuticals GmbH, Zyngenia, Inc., Molecular Templates Inc., Otsuka Holdings Co., Ltd., Gliknik, Inc., Celleron Therapeutics Ltd, Immunovative Therapies, Ltd., Targazyme, Inc., Advancell, Vaxil Bio Therapeutics Ltd., Igenica, Inc., Selvita S.A, Karyopharm Therapeutics, Inc., APIM Therapeutics AS, Kancera AB, Jasco Pharmaceuticals, LLC., OncoPep Inc., Rhizen Pharmaceuticals SA, Formula Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., Modulation Therapeutics, Inc., AbbVie Inc., cCAM Biotherapeutics Ltd., BioNovion B.V., Senhwa Biosciences
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Relapsed Multiple Myeloma - Pipeline Review, H1 2014
- Refractory Multiple Myeloma - Pipeline Review, H1 2014
- Multiple Sclerosis - Pipeline Review, H1 2014
- Inflammatory Bowel Disease - Pipeline Review, H1 2014
- Parkinson's Disease - Pipeline Review, H1 2014
- Alzheimer's Disease - Pipeline Review, H1 2014
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- Crohn's Disease - Pipeline Review, H1 2014
- Huntington's Disease - Pipeline Review, H1 2014
- Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014